Medicine Recommendations

Osteoarthritis

NICE CG177 - Osteoarthritis: Care and management in adults

Narcolepsy with cataplexy

Unlicensed as a mood stabiliser

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

National Patient Safety Alert:  Valproate: organisations to prepare for new regulatory measures for oversight of prescribing to new patients and existing female patients

Hyperkalaemia

NICE TA599 - Sodium Zirconium Cyclosilicate for treating Hyperkalaemia

Treatment of Storage Symptoms associated with Benign Prostatic Hyperplasia

*FOR FYLDE & WYRE CCG ONLY* - For use in men who were already taking tamsulosin with some response; however the response was not adequate.

*FOR MORECAMBE BAY CCG ONLY* - Not to be used as first line

Treating excessive daytime sleepiness caused by narcolepsy (NICE TA758)

NICE TA 758 - Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy

Treating growth disturbance in children and young people aged 3 years and over (NICE TA863)

NICE TA863 - Somatrogon for treating growth disturbance in children and young people aged 3 years and over

Adult growth hormone deficiency (NICE TA64) & Growth failure in children (NICE TA188)

Sotagliflozin with insulin for treating type 1 diabetes (TA 622)

Acne Vulgaris

Idiopathic hyperandrogenism and polycystic ovary syndrome

Nasal allergies

Adjunctive therapy of refractory generalised tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (Dravet syndrome) in combination with clobazam and valproate (under expert supervision)

All indications

Treatment of severe osteoporosis

- in postmenopausal women;

- in adult men

at high risk of fracture, for whom treatment with other medicinal products approved for the treatment of osteoporosis is not possible due to, for example, contraindications or intolerance. In postmenopausal women, strontium ranelate reduces the risk of vertebral and hip fractures.

The decision to prescribe strontium ranelate should be based on an assessment of the individual patient's overall risks

MHRA Drug Safety Update - Strontium ranelate: cardiovascular risk—restricted indication and new monitoring requirements (March 2014)

Radiation proctitis

Bile acid gastritis

Crohn's disease

Rheumatoid arthritis

Sero-negative spondyloarthropathy including psoriatic arthritis & psoriasis (unlicensed)